Full history for every metric is available with a Kvantra account
PharmAust Limited (PAA.AX)
Key financial summary
Financials in AUD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 4 | 3 | 2 | 3 | 3 | 0 | 1 |
| Operating profit | AUD m | -7 | -7 | |||||
| Net profit | AUD m | -2 | -1 | -1 | -2 | -6 | -9 | -8 |
| EPS reported | AUD | -0.02 | -0.02 | |||||
| Operating cashflow per share | AUD | -0.01 | -0.01 | |||||
| Capex per share | AUD | 0.00 | 0.00 | |||||
| FCF per share | AUD | -0.01 | -0.01 | |||||
| Free cash flow | AUD m | -5 | -5 | |||||
| Net debt | AUD m | -10 | -10 | |||||
| Book value equity | AUD m | 10 | 10 | |||||
| Book value per share | AUD | 0.03 | 0.02 | |||||
| Number of shares | m | 370.81 | 445.02 | |||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 7.07 | 10.94 | |||||
| P/S LTM | x | 0.00 | 130.55 | |||||
| P/FCF LTM | x | -13.99 | -21.66 | |||||
| EV/EBITDA LTM | x | -6.62 | -10.81 | |||||
| EV/Sales LTM | x | 0.00 | 119.21 | |||||
| Earnings Yield LTM | % | -12.49% | -10.59% | |||||
| FCF Yield | % | -7.15% | -4.62% | |||||
| Quality | ||||||||
| ROE | % | -88.31% | -127.96% | |||||
| ROIC | % | -61.29% | -61.29% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -100.00% | -100.00% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 1.03 | 1.03 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -13.44% | -8.68% | |||||
| Net debt/Equity | x | -0.95 | -0.95 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PharmAust Limited (PAA.AX)
Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free